From 2017 to 2022, Mr. Levine was the Chief Financial Officer of Oncocyte (OCX: NasdaqGM) a molecular diagnostic company, where he oversaw corporate growth from eight employees to more than 120; conducted 10 capital raises bringing the company to fully-funded status; built the shareholder base from one institutional investor to more than 50;  negotiated and integrated three acquisitions; and secured the largest licensing deal in company history with one of the largest and fastest-growing diagnostic laboratories in China. From 2000 to 2017, Mr. Levine was Founder and Managing Member of Enable Capital Management, LLC, whose underlying investment vehicle, Enable Growth Partners, LP, was one of the largest funds providing growth capital to small and mid-sized public and private companies. Prior to Enable Capital Management, Mr. Levine was a Founding Member of the Shemano Group, a San Francisco-based investment bank focused on the capital needs of technology and life science companies where Mr. Levine was widely recognized for originating and developing one of the largest alternative financing markets in the US, generating more than $100 billion of financings annually.